Identification of a Plausible Inhibitor of SARS-Cov 2 Protease (6LU7) and the Spike Envelope Glycoprotein (6MOJ) from Active Compounds of Nigella sativa: An In-silico Approach
SARS-CoV-2, the recent disease outbreak causing respiratory tract illness, raised as the global health burden that has caused significant morbidity and mortality worldwide. In the ongoing transmission of this pandemic virus, its control is very challenging due to the lack of specific treatment. The compelling situation feels the necessity for the use of all assets to cure this disease. SARS-CoV-2, main protease, and spike envelope glycoprotein are important determinants in the infectious virus process, and targeting these proteins is gaining importance in anti-CoV drug design. In these conceptual circumstances, an attempt has been made to suggest an in silico molecular docking approach to identify new probable leads from the active constituents from Nigella sativa L against protein target main protease(6LU7) and spike envelope glycoprotein(6MOJ). Our results indicate that Nigellicine and Nigellicimine N-Oxide towards main protease and Nigellamine A5 and Nigellamine A1 towards spike glycoprotein has potential antiviral protein binding affinity among others forming good interactions. Thus, these compounds may be considered to be potential inhibitors against SARS-CoV-2 but need to be explored for further evaluations are recommended.